共 199 条
[1]
Baselga J(2009)Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nat Rev Cancer 9 463-475
[2]
Swain SM(2009)Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models Cancer Res 69 9330-9336
[3]
Scheuer W(2002)Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo Clin Cancer Res 8 1720-1730
[4]
Friess T(2004)A comparison of the in vitro and in vivo activities of IgG and F(ab’)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies Clin Cancer Res 10 3542-3551
[5]
Burtscher H(2004)The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells Cancer Res 64 2343-2346
[6]
Bossenmaier B(2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 25-32
[7]
Endl J(2013)Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 14 461-471
[8]
Hasmann M(2010)CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer Clin Breast Cancer 10 489-491
[9]
Spiridon CI(2014)First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer Clin Cancer Res 20 5359-5364
[10]
Ghetie MA(2012)Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 109-119